June 30, 2024
Headlines

Healthcare

Mammha Secures Vital Funding from American Heart Association to Advance Perinatal Mental Health Solutions

Editor04 mins

Mammha, a pioneering provider of perinatal mental health care solutions, proudly announces a significant funding infusion from the American Heart Association Social Impact Funds. This transformative support, awarded on June 5th, 2024, is poised to propel Mammha’s innovative initiatives aimed at enhancing mental health services for parents and healthcare providers nationwide. The American Heart Association’s…

Read More

Waypoint Bio Launches with $14.5M to Revolutionize Solid Tumor Therapy Through Innovative Drug Discovery Technology

Editor04 mins

Waypoint Bio, a pioneering biotechnology firm, has secured $14.5 million in seed funding led by Hummingbird Ventures, alongside Recode Ventures and Fifty Years, to advance its cutting-edge approach in developing cell therapies for solid tumors. Founded by MIT alumni Xinchen Wang and David Phizicky, Waypoint Bio harnesses in vivo spatial pooled screening technology to drive…

Read More

RareCyte Secures $20M to Expand Orion™ Spatial Biology Platform and Precision Biology Services

Editor04 mins

RareCyte, Inc., a pioneering Life Sciences company renowned for its Precision Biology platforms, has announced the successful completion of a $20 million financing round aimed at bolstering its Orion™ Spatial Biology platform. This funding, sourced from a blend of new and existing investors, including Forest Road, Arboretum Ventures, and F-Prime Capital, underscores RareCyte’s commitment to…

Read More

NeOnc Technologies Secures $18.5 Million to Propel Breakthrough Brain Cancer Therapies Through Phase II Trials

Editor05 mins

NeOnc Technologies Holdings, Inc., a forefront player in clinical-stage biotechnology, has successfully concluded an $18.5 million financing round aimed at advancing its innovative approach to treating brain cancer. This funding milestone includes new equity investment and debt conversions, reflecting a substantial increase in NeOnc’s valuation and reinforcing its commitment to pioneering neurological therapeutics. The financing…

Read More

Augustine Therapeutics Secures EUR 17 Million in Series A Funding to Propel Groundbreaking Neurological Disease Treatment

Editor05 mins

Augustine Therapeutics, a pioneering biotechnology firm specializing in innovative therapies for neurodegenerative and cardiometabolic diseases, announced a significant milestone today with the successful completion of a EUR 17 million (USD 18.5 million) first closing of its Series A funding round. This financing, led by Asabys Partners and supported by Eli Lilly and Company and the…

Read More

Transformative Health Insurance Innovator Sidecar Health Secures $165M Series D Funding Led by Koch Disruptive Technologies

Editor06 mins

Sidecar Health, a pioneering force in revolutionizing health insurance accessibility and transparency, proudly announces the successful closure of a monumental $165 million Series D financing round. Koch Disruptive Technologies spearheaded this investment, marking the largest private funding initiative in employer health benefits this year. Joining forces with existing investors such as GreatPoint Ventures, BOND, and…

Read More

Sensi.AI Secures $31 Million to Transform Senior Care with Revolutionary AI Technology

Editor07 mins

Sensi.AI, a pioneering leader in care intelligence, has announced a significant milestone with the successful completion of a $31 million Series B funding round. This latest infusion, co-led by Zeev Ventures and Insight Partners, alongside existing investors Entrée Capital, Flint Capital, Jibe Ventures, and Secret Chord Ventures, brings Sensi.AI’s total funding to over $53 million….

Read More

UroMems Raises $47 Million in Series C Funding to Advance Groundbreaking Treatment for Stress Urinary Incontinence

Editor05 mins

UroMems, a pioneering global company specializing in mechatronics technology for treating stress urinary incontinence (SUI), has secured $47 million in its Series C financing round, marking a record fundraising achievement for the company. This capital infusion will propel pivotal clinical trials of their groundbreaking UroActive™ System, the world’s first smart automated artificial urinary sphincter (AUS)…

Read More

Ethris GmbH: Leading the Charge in mRNA-Based Therapeutics with $5 Million Investment

Editor04 mins

Since its inception, Ethris GmbH has been a trailblazer in mRNA technology, revolutionizing the biotech landscape with its innovative approach to respiratory and cardiovascular diseases. Founded on a vision of harnessing messenger RNA (mRNA) for therapeutic breakthroughs, Ethris has consistently pushed boundaries, drawing attention from investors and global biotech leaders alike. Breakthroughs and Strategic Growth…

Read More

PolTREG Reports Long-Term Success in Type-1 Diabetes Treatment Study

Editor03 mins

PolTREG S.A., a pioneering biotechnology firm specializing in cellular therapies for autoimmune disorders, has announced groundbreaking findings from its long-term clinical study on PTG-007, a polyclonal Treg cell therapy for early-onset type-1 diabetes (T1D). Over a span of 7 to 12 years, pediatric patients treated with PTG-007 demonstrated sustained insulin secretion, contrasting starkly with a…

Read More